

Tim Luetkens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5786919/publications.pdf>

Version: 2024-02-01

41
papers

1,429
citations

304743

22
h-index

345221

36
g-index

45
all docs

45
docs citations

45
times ranked

2661
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. <i>British Journal of Cancer</i> , 2008, 99, 930-938.	6.4	106
2	Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 918-922.	4.1	95
3	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. <i>Leukemia</i> , 2014, 28, 993-1000.	7.2	92
4	Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. <i>Haematologica</i> , 2010, 95, 785-793.	3.5	87
5	The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. <i>Experimental Hematology</i> , 2010, 38, 860-867.	0.4	72
6	Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 1343-1352.	7.0	70
7	Decrease of CD4+FOXP3+ T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor. <i>Psychoneuroendocrinology</i> , 2010, 35, 663-673.	2.7	63
8	CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. <i>Haematologica</i> , 2008, 93, 423-430.	3.5	59
9	Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 685-698.	2.5	53
10	NY-ESO-1/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 381-393.	5.1	52
11	An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. <i>Journal of Immunological Methods</i> , 2010, 358, 56-65.	1.4	46
12	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. <i>International Journal of Cancer</i> , 2014, 135, 1142-1152.	5.1	46
13	CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. <i>Nature Communications</i> , 2020, 11, 798.	12.8	43
14	Role of immunotherapy in Ewing sarcoma. , 2020, 8, e000653.		42
15	Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. <i>Leukemia</i> , 2022, 36, 1943-1946.	7.2	41
16	5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity. <i>Mediators of Inflammation</i> , 2014, 2014, 1-12.	3.0	37
17	In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. <i>Leukemia</i> , 2020, 34, 317-321.	7.2	34
18	Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 1647-1655.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Immunotherapies targeting CD38 in Multiple Myeloma. <i>Oncolmmunology</i> , 2016, 5, e1217374.	4.6	33
20	CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1606-1611.	3.3	26
21	The promise of adoptive cellular immunotherapies in hepatocellular carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1673129.	4.6	26
22	Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. <i>Experimental and Molecular Pathology</i> , 2010, 89, 175-181.	2.1	25
23	Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-8.	3.3	24
24	The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2533-2542.	3.3	21
25	Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. <i>Oncolmmunology</i> , 2017, 6, e1308618.	4.6	21
26	Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, e1391.	3.8	21
27	Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. <i>Blood Advances</i> , 2020, 4, 4864-4868.	5.2	20
28	Biomarkers for checkpoint inhibition in hematologic malignancies. <i>Seminars in Cancer Biology</i> , 2018, 52, 198-206.	9.6	18
29	Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1151-1162.	4.2	17
30	Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. <i>Trends in Biotechnology</i> , 2022, 40, 875-890.	9.3	17
31	Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 839-845.	1.6	11
32	Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma. <i>British Journal of Haematology</i> , 2015, 171, 752-762.	2.5	10
33	Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. <i>Oncotarget</i> , 2017, 8, 49253-49263.	1.8	10
34	Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-10.	3.3	9
35	Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	9
36	The role of surface molecule CD229 in Multiple Myeloma. <i>Clinical Immunology</i> , 2019, 204, 69-73.	3.2	9

#	ARTICLE	IF	CITATIONS
37	Deep dissection of the antiviral immune profile of patients with COVID-19. <i>Communications Biology</i> , 2021, 4, 1389.	4.4	9
38	Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. <i>Journal of Translational Medicine</i> , 2015, 13, 197.	4.4	6
39	Elotuzumab as a novel anti-myeloma immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1751-1757.	3.3	6
40	Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant. <i>Vaccines</i> , 2021, 9, 737.	4.4	5
41	Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy. <i>Blood</i> , 2008, 112, 3668-3668.	1.4	1